China’s SciNeuro, Novartis sign US$1.7 billion licensing deal to develop Alzheimer’s drugs

    China’s SciNeuro, Novartis sign US$1.7 billion licensing deal to develop Alzheimer’s drugs

    A partnership between China’s SciNeuro Pharmaceuticals and Swiss pharmaceutical giant Novartis on Monday has revived hopes for treating Alzheimer’s disease. The deal, worth nearly US$1.7 billion, grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro’s antibody candidates to develop drugs for the progressive brain disease. SciNeuro’s novel amyloid beta targeted antibody programme leverages proprietary…

    Read More
    Yahoo news home

    Ending polio still possible, health officials say, as funding cut by 30%

    (Corrects ‘infection’ to ‘disease’ in paragraph 5 to clarify what the inactivated polio vaccine protects against, whether dosed fully or fractionally) By Jennifer Rigby LONDON (Reuters) -Eradicating polio is still possible despite significant funding cuts, global health officials said on Tuesday as they outlined how they will cope with the shortfall. The budget of the…

    Read More